ALB and Cirrhosis: We did further subgroup analysis to explore whether liver disease background influenced ALB level after treatment, which showed that MSC therapy was related to an increased level of ALB at 4 weeks (MD 1.88, 95% CI 1.31–2.46, P < 0.00001) and 24 weeks (MD 4.55, 95% CI 3.20–5.91, P < 0.0001) in both the ACLF and cirrhosis subgroups (Fig. 6).